FDA,CMS Build Drug Safety System Prototype
This article was originally published in The Pink Sheet Daily
Executive Summary
Coming Medicare final rule enables FDA to access Part D data for public health and safety research.
You may also be interested in...
Sweeping Changes At CDER Recommended In IoM Drug Safety Report
Among solutions suggested is six-year fixed term for the FDA commissioner and appointment of external advisory board to oversee cultural changes.
AstraZeneca/FibroGen’s Roxadustat Comparison To ESAs In Anemia May By Clarified At FDA Advisory Cmte.
Payers would welcome any additional clarity provided by advisory panel review, given the perception, expressed in a recent ICER report, that the evidence is insufficient to determine whether the new drug is safer or more effective than erythropoiesis-stimulating agents.
Medicare Drug Pricing Demonstration Agenda May Be Reshaped By Fowler As CMMI Head
Elizabeth Fowler brings combination of Capitol Hill, White House and pharma industry experience to the role of director of the Center for Medicare and Medicaid Innovation.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: